67. 多発性嚢胞腎 Polycystic kidney disease Clinical trials / Disease details


臨床試験数 : 216 薬物数 : 219 - (DrugBank : 50) / 標的遺伝子数 : 39 - 標的パスウェイ数 : 151

  
12 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT02055079
(ClinicalTrials.gov)
April 201431/1/2014Pulsed Oral Sirolimus in Autosomal Dominant Polycystic Kidney DiseasePulsed Oral Sirolimus in Autosomal Dominant Polycystic Kidney Disease - The Vienna RAP StudyPolycystic Kidney, Type 1 Autosomal Dominant Disease;Polycystic Kidney, Type 2 Autosomal Dominant DiseaseDrug: Sirolimus;Drug: PlaceboMedical University of ViennaNULLUnknown status18 YearsN/AAll68Phase 3Austria
2EUCTR2012-000550-60-AT
(EUCTR)
17/01/201427/11/2013Pulsed oral sirolimus in autosomal dominant polycystic kidney diseasePulsed oral sirolimus in autosomal dominant polycystic kidney disease - The Vienna RAP Study Autosomal dominant polycystic kidney disease (ADPKD) is a genetic disorder characterized by the development and uncontrolled proliferation of innumerable epithelial-lined cysts that stem from renal tubular cells, which compress and/or destroy vital renal tissue with a gradual decline in renal function, and terminal kidney failure with the need for renal reaplacement therapy. As yet, other than supportive care there is no viable therapy.
MedDRA version: 20.0;Level: LLT;Classification code 10036046;Term: Polycystic kidney, autosomal dominant;System Organ Class: 100000004850;Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16]
Trade Name: Rapamune 1mg tablets
Product Name: Rapamune 1mg tablets
INN or Proposed INN: SIROLIMUS
Medizinische Universität Wien, Klinische Abteilung für Nephrologie und Dialyse, Universitätsklinik für Innere Medizin 3NULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
68Phase 3Austria
3NCT01680250
(ClinicalTrials.gov)
September 201130/8/2012Sirolimus for Massive Polycystic LiverAn Open-label, Prospective Clinical Trial to Evaluate the Effectiveness and Safety of Sirolimus to Reduce Cyst Growth in ADPKD Patients With Massive Polycystic LiverPolycystic Kidney DiseasesDrug: SirolimusSeoul National University HospitalWyeth is now a wholly owned subsidiary of PfizerRecruiting18 Years65 YearsBoth44Phase 2/Phase 3Korea, Republic of
4NCT01223755
(ClinicalTrials.gov)
September 201012/10/2010Sirolimus In Autosomal Dominant Polycystic Kidney Disease And Severe Renal InsufficiencyEFFECTS OF SIROLIMUS ON DISEASE PROGRESSION IN PATIENTS WITH AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE AND SEVERE RENAL INSUFFICIENCYAutosomal Dominant Polycystic Kidney Disease (ADPKD)Drug: Sirolimus;Drug: conventional therapyMario Negri Institute for Pharmacological ResearchNULLTerminated18 Years80 YearsBoth41Phase 2/Phase 3Italy
5NCT01632605
(ClinicalTrials.gov)
November 200913/5/2012The Vienna RAP Pilot StudyRapamycin in Advanced Polycystic Kidney Disease Pilot StudyADPKDDrug: SirolimusMedical University of ViennaNULLCompleted18 YearsN/ABoth8N/AAustria
6NCT00920309
(ClinicalTrials.gov)
June 200912/6/2009Rapamycin as Treatment for Autosomal Dominant Polycystic Kidney Disease (ADPKD): The Role of Biomarkers in Predicting a Response to TherapyRapamycin as Treatment for ADPKD: The Role of Biomarkers in Predicting a Response to TherapyAutosomal Dominant Polycystic Kidney DiseaseDrug: Rapamycin;Other: Standard of Care-PlaceboYale UniversityNULLTerminated18 Years70 YearsAll21Phase 2/Phase 3United States
7EUCTR2007-005047-21-IT
(EUCTR)
24/12/200702/07/2008Effects of Sirolimus on disease progression in patients with Autosomal Dominant Polycystic Kidney Disease and severe renal insufficiency - SIRENA IIEffects of Sirolimus on disease progression in patients with Autosomal Dominant Polycystic Kidney Disease and severe renal insufficiency - SIRENA II Autosomal Dominant Polycystic Kidney Disease (ADPKD)
MedDRA version: 9.1;Level: LLT;Classification code 10010428;Term: Congenital cystic kidney disease
Trade Name: RAPAMUNE*100CPR RIV 1MG
INN or Proposed INN: Sirolimus
Trade Name: RAPAMUNE*30CPR RIV 2MG
INN or Proposed INN: Sirolimus
IST. DI RICERCHE FARMACOLOG. M. NEGRINULLNot Recruiting Female: yes
Male: yes
40 Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): yes Therapeutic confirmatory - (Phase 3): no Therapeutic use (Phase 4): noItaly
8EUCTR2007-006557-25-IT
(EUCTR)
20/12/200718/12/2007RAPAMYCIN FOR TREATMENT OF AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE - RAPYD-STUDYRAPAMYCIN FOR TREATMENT OF AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE - RAPYD-STUDY ADPKD type I
MedDRA version: 9.1;Level: SOC;Classification code 10038359;Term: Renal and urinary disorders
Trade Name: RAPAMUNE*100CPR RIV 1MG
INN or Proposed INN: Sirolimus
Product Name: Ramipril
INN or Proposed INN: Ramipril
AZIENDA OSPEDALIERA OSPEDALE POLICLINICO CONSORZIALENULLNot RecruitingFemale: yes
Male: yes
Italy
9NCT00491517
(ClinicalTrials.gov)
March 200725/6/2007Sirolimus Treatment in Patients With Autosomal Dominant Polycystic Kidney Disease: Renal Efficacy and SafetySirolimus Treatment in Patients With ADPKDPolycystic KidneyDrug: Sirolimus;Drug: conventional therapyMario Negri Institute for Pharmacological ResearchNULLCompleted18 Years80 YearsBoth22Phase 2Italy
10EUCTR2006-003427-37-IT
(EUCTR)
05/02/200727/12/2006Sirolimus treatment in patients with autosomal dominant polycystic kidney disease renal efficacy and safety - NDSirolimus treatment in patients with autosomal dominant polycystic kidney disease renal efficacy and safety - ND Autosomal-Dominant Polycystic Kidney Disease ADPKD
MedDRA version: 9.1;Level: LLT;Classification code 10010428;Term: Congenital cystic kidney disease
Trade Name: RAPAMUNE*30CPR RIV 1MG
INN or Proposed INN: Sirolimus
Trade Name: RAPAMUNE*30CPR RIV 2MG
INN or Proposed INN: Sirolimus
IST. DI RICERCHE FARMACOLOG. M. NEGRINULLNot Recruiting Female: yes
Male: yes
16 Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): yes Therapeutic confirmatory - (Phase 3): no Therapeutic use (Phase 4): noItaly
11NCT00286156
(ClinicalTrials.gov)
October 20061/2/2006Pilot Study of Rapamycin as Treatment for Autosomal Dominant Polycystic Kidney Disease (ADPKD)Pilot Study of Rapamycin as Treatment for Autosomal Dominant Polycystic Kidney DiseasePolycystic Kidney DiseasesDrug: RapamuneThe Cleveland ClinicWyeth is now a wholly owned subsidiary of PfizerCompleted18 Years75 YearsAll30Phase 1/Phase 2United States
12NCT00346918
(ClinicalTrials.gov)
June 200622/6/2006Sirolimus (Rapamune®) for Autosomal Dominant Polycystic Kidney Disease (ADPKD)Sirolimus (Rapamune®) for Patients With Autosomal Dominant Polycystic Kidney Disease (ADPKD): a Randomized Controlled Study.Autosomal Dominant Polycystic Kidney Disease (ADPKD)Drug: Sirolimus;Other: StandardUniversity of ZurichNULLCompleted18 Years40 YearsBoth100Phase 3Switzerland